BIIB Stock Biogen Inc - Complete Overview

Nasdaq / Pharmaceutical Products / Healthcare / BIIB Stock

Biogen Inc (BIIB) price per share as of 20 Apr 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 211.56M
Avg Daily Volume 1.69M
Market Cap 73.2B
Volatility 26.34% MEDIUM

BIOGEN INC (BIIB) OVERVIEW

BIIB stock is a pharmaceutical products company traded on Nasdaq. It is valued at 73.2B US dollars. There are 211.56M shares outstanding which Biogen Inc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 26.34% stock on average. It brought investors a total return of -3.63% over the last 12 months. Biogen Inc stock is relatively cheap. It's P/E ratio is below the market average.

Biogen Inc (BIIB) STOCK PRICE PERFORMANCE

BIIB SHAREHOLDER'S RETURN

Earnings Per Share 11.94
Dividends Per Share 0.00
12 Months Price Performance Negative
Total Return Negative

BIIB LATEST NEWS

Why Is Biogen Inc. Giving Ionis Another $1 Billion?

Biogen recently doubled down on its investment into Ionis Pharmaceuticals. Here's what you need to know.

What's in Store for Biogen (BIIB) This Earnings Season?

On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

Ionis Pharmaceuticals' stock soars as Biogen collaboration deal includes $1 billion payment

Shares of Ionis Pharmaceuticals Inc. soared 8.4% in premarket trade Friday, after Biogen Inc. said it would pay the company $1 billion as part of a new 10-year collaboration agreement to develop drug candidates to treat neurological diseases. Biogen's stock was still inactive. Part of the payment will include $625 million to buy about 11.5 million Ionis shares, or about 9.2% of the shares outstanding, at $54.34 a share, which is 18.5% above Thursday's closing price of $45.85. Biogen will have the option to license therapies and will be responsible for their development and commercialization, and may make milestone payments, license fees and royalties to Ionis on net sales. The deal is expected to close in the second quarter of 2018. Ionis's stock had lost 8.9% year to date through Thursday, while Biogen shares had tumbled 16.5%, the iShares Nasdaq Biotechnology ETF had slipped 0.8% and the S&P 500 had gained 0.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Is It Time to Give Up on Alkermes?

It feels like we've been here before.

2 Small Biotechs To Buy This Week

Today, we profile two small biotech stocks that are 'Busted IPOs' Both are attractive risk/reward plays at current trading levels. We take a look at these two names in depth in the paragraphs below.

Better Buy: Biogen Inc. vs. Amgen Inc.

Which stock wins in a battle of big biotechs?

Biogen Inc (BIIB) TECHNICAL INDICATORS

Name Value Action
RSI(14) 41.18 Neutral
CMO(14) -17.64 Sell
ADX(14) 45.53 N/A
Williams %R -54.21 Overbought

BIIB STOCK VALUATION

BIIB Industry Sector Market
Price to Earnings 28.98 32.53 28.84 45.62
Price to Book Value 5.80 6.82 6.57 7.00
Price to Sales 5.96 3.95 3.69 5.00
Return on Equity 20.90% 12.78% 11.13% 17.71%
Return on Assets 11.30% 6.01% 4.94% 8.04%
All values TTM (trailing twelve months). Source: Quandl.com

BIIB FORUM DISCUSSIONS